Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
77 hedge funds and large institutions have $1.28B invested in Adaptimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 11 closing their positions.
403% more capital invested
Capital invested by funds: $255M → $1.28B (+$1.03B)
273% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 11
64% more funds holding
Funds holding: 47 → 77 (+30)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
22.02% more ownership
Funds ownership: 60.08% → 82.09% (+22%)
49% less call options, than puts
Call options by funds: $5.46M | Put options by funds: $10.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$62.8M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$28.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$18.7M |
| 4 |
RI
RTW Investments
New York
|
+$16.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.87M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$2.04M |
| 3 |
Renaissance Technologies
New York
|
-$280K |
| 4 |
WM
WS Management
Jacksonville,
Florida
|
-$131K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$65.3K |
ADAP Hedge Fund Activity: Q2 2020 in Review
77 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2020, worth a combined $1.28B — up 403% from $255M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ADAP positions and 11 closed out — a net gain of 30 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $62.8M. The largest seller was OrbiMed, exiting entirely with an estimated $6.87M sold.
- 77 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2020, up from 47 in Q1 2020.
- Funds reported $1.28B of Adaptimmune Therapeutics stock for Q2 2020, up 403% quarter-over-quarter.
- 41 funds opened new Adaptimmune Therapeutics positions in Q2 2020 and 11 closed out, a net change of +30 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2020 was Avoro Capital Advisors, an estimated $62.8M added.
- The largest Adaptimmune Therapeutics seller in Q2 2020 was OrbiMed, an estimated $6.87M sold.
Based on aggregated 13F filings for Q2 2020.